European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020

COVID-19 care options: Facts and Challenges

Dr.Nandhana Prashanth V Assistant Professor[1],

Dr.Ravikanth P Senior Resident[2]

Meenakshi Academy of Higher Education and Research

nandhanaprashanthv@mmchri.ac.in

Abstract

In December 2019, an outbreak due to extreme acute Coronavirus 2 (SARS-Cow-2) respiratory syndrome was first identified in Wuhan, China. The 2019 global coronavirus disease (COVID-19) pandemic in 2020 culminated in an extraordinarily strong risk for spreading. No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp). No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp). No medications in large-scale trials have been validated with substantial effectiveness of clinical care for COVID-19 patients considering the declining pattern of COVID-19. Remdesivir is deemed the most promising antiviral agent; it acts by inhibiting RNA-dependent polymerase RNA function (RdRp).

Keywords: Coronavirus, , patients, Remddesivir, SARS-CoV-2, treatment

Introduction

Wuhan City (the capital of Hubei Province, China) witnessed a significant outbreak of a new coronavirus in December 2019. It was discovered that this epidemic was triggered by a new virus, an extreme acute coronavirus syndrome 2 (SARS-CoV-2). Several clinical SARS-Co-2 cases were identified and spread to over half the world's countries for less than 6 months (data till March 28, 2020).[1] The main focus of SARS-CoV-2 contamination is the lower

respiratory tract. It is worth remembering that adults with coronavirus disease 2019 (COVID-19) also have a deep decline in the early stages of this disease both CD4β and CD4β T-cell subsets. Patients were consequently impaired by acute breathing disturbance syndrome for approximately 7e10 days after beginning COVID-19 because of accelerated viral réplication, stormy development in pro-inflammatory cytokines as well as chemokine reaction and inflammatory cell infiltrates. However, unlike 2003 SARS, 10 patients suffering from a SARS-CoV-2 infection did not experience prodromal symptoms of high respiratory tract infection (e.g., coughing, sore throat, rhinorrhea), viremia-related oratory abnormalities (e.g. leukopenia, psoria, anemia, elevated liver enzymes and dehydration of the gene), or initial tests of diagnostic chest roentgenographic abnormalities. Furthermore, unknown seasonality and the incubation time of 2-14 days for SARS-CoV-2, render it surprisingly challenging for early diagnoses and early care to be initiated.[2] Previous experiments have shown that human coronavirus-NL63 (HCoV-NL63) can be used as a cell receptor in human beings utilising angiotensin-transforming enzyme-2 (ACE2). Although children are known to be slightly less prone to HCov-NL63 and have less severe disorders than adults. The SARS-CoV-2 infection has been a public health concern for citizens around the world because of its strong capacity for contact and its unpredictability of disadvantage. For the intention of containing the SARS-CoV-2 spread among community members, the Centers for Disease Control (CDC) and Taiwan Prevention have been introducing robust infection control initiatives since February 20, 2020.[3] In a study, 15 patients with SARS-CoV infection experienced the largest viral load closer when submitted (measured from back oropharyngeal saliva samples). One research suggested that since the viral load had peaked about the time of hospital entry, early use of strong antivirals may help control the severity of COVID-19. However, there is currently no standard therapy for COVID-19. The functions of several medications, including antivirals, antibiotics and anti-inflammatory drugs, were examined to examine their effectiveness in the battle against SARS-CoV-2 (data until March 28, 2020).

Remdesivir

The most successful, optimistic antiviral therapy is considered to be 16 remdesivir (GS-5734; Gilead Sciences, Inc., Foster City, CA, USA) among many possible drugs evaluated for efficacy in treating the SARS-CoV-2 infection. It functions by targeting RNA RNA polymerase viral (RdRp) thus preventing revision by viral exoribonucleic ase, this results in the premature termination of the transcription of viral RNA.[4] Unlike other nucleotide analogues, remdesi-vir is a large-spectrum phosphoramidate treatment for several groups of

viruses including Filoviridae, Paramyxoviridae, Pneumoviridae and Orthocaronavirinae (such as pathogenic SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]). Knowledge concerning human remdesivir pharmacokinetics is not accessible. However, useful evidence from the rhesus monkeys showed a 10 mg/kg dosage of remdesivir for at least 24 h.20 intracellulite in the peripheral blood mononuclear cells could contribute to a surprisingly high concentration (>10 mm) of active triphosphate in the treatment of the SARS-CoV-2 infection of human blood. In addition, the results on human recurrence protection were accessible online. On January, 2020, the first COVID-19 patient in the United States was successfully treated on remdesivir for pneumonia gression on day 7 of hospitalization. Phase 3 human tests have been conducted (ClinicalTrials.gov Identifier: NCT04292899 and NCT04292730, respectively for severe and moderate SARS-CoV-2 adult cases). On day 1, 200 mg were issued, accompanied by 100 mg once daily on day 2. Despite its promoting strong in vitro tenor to SARS-CoV-2 and clinical performance in COVID-19, concerns regarding negative consequences (e.g. nausea, vomiting, rectal haemorrhage and hepatic toxicity) and clinical effectiveness of remdesivir have been recently recorded.[5] In a mouse model that examined the pathogenesis of SARS-CoV, a pro-duce substantial reduction in viral lung stress (i.e.,>2 orders in magnitude on the second day of 2e5 post-infection) was shown to reduce disease development and enhance respiratory functions significantly. Brown et al. further noted the existence of remdesivir in tissue culture model half-maximum effective concentrations (EC50s) of 0.069 mM for SARS-CoV and 0.074 mM for MERS-CoV.23 Moreover studies in tissue culture have also shown that several extremely divergent CoVs, including the endemic human coVs (HCoV-OC43, HCoV-229E) and zoonotic coV, are effectively inhibited by remdessivir in su, respectively. Notice that in a non-human primate model (rheumococcal-macca) of the MERS-CoV infection, comparable efficacy of prophylactic and therapeutic remdesivir therapy (24 hours before inoculation and 12 hours postinoculation), was also shown. While two amino acid substitutions (F476L and V553L) in the non-structural protein, 12 polymerases were shown to impart low levels of resistance.[17]

Favipiravir

Favipiravir's other RdRp-inhibitor (Fujifilm Toyama Chemical Co. Ltd., Tokyo, Japan) is well-known to be involved in vitro in the battle against influenza A, B, and C. Favipiravir is readily identified as a subcontractor of viral RNA in several RNA viruses, until transformed into an active phosphorus-ibosylated form. The prescribed influenza dosage is 1600 mg

orally administered twice daily on day 1, then 600 mg orally twice daily on day 2e5, and 600 mg once daily on day 6. Preliminary findings of clinical trials recently revealed that favoripiravir has promising potential to treat Chinese SARS-CoV-2 patients.[4] Favipiravir was licenced in March 2020 for COVID-19 care in China. In addition, the effectiveness of favipiravir plus interferon-a (ChiCTR2000029600) and favipiravir plus baloxavir marboxil was recruited to randomised studies in COVID- 19 patients (ChiCTR2000029544).[6]

Ribavirin

Ribavirin (Bausch Health Companies Inc., Bridgewater, NJ, USA) is an analogue antiviral medication used to combat many infectious diseases such as hepatitis C, airborne syncytial viruses (RSV) and certain viral hemorrhagic fevers.[3] The predicted in-viral activity of ribavirin against SARS-CoV is 50 mg/mL.29 However, haemoglobin loss has a detrimental impact that is dangerous to patients with breathing disorders.

Interferons

Interferon b (IFNb)-1b (Bayer Pharmaceutical Co., Leverkusen), an immunomodulatory agent, was shown to induce clinical improvement in typical MERS-CoV marmots infected but the effects of IFNb-1b for patients suffering from SARS remain unclear.

Other considerations and precautions regarding concomitant medication

Analysis by Yang et al. (2020)62 found that cerebrovascular disease and diabetes were the most defining substances among non-survivors of COVID-19 in intensive care units.[3] Guan et al. have also found related observations (2020; The ACE or angiotensin II type I blocker receptor patients is typically cared for these patients (ARB). 5.12 SARS-CoV-2 and SARS-CoV, as described above, may connect their target cells through ACE2 receptors expressed by the lung, intestine, and kidney epithelial cells. Acetaminophhen might be a safer option than NSAIDs for criticised adults with CAVID-19 who have acquired fever. According to the Wu et al. report (2020), COVID-19 therapy with methylprednisolone was found to minimise the incidence of fatality (HR, 0.38; 95% CI, 0.20e0.72). The dosage of methylprednisolone prescribed in this investigation is not therefore defined. Given the absence of data, some critical care professionals are promoting the usage of low dose corticosteroid treatment (intravenous hydrocortisone, for example 200 mg a day), in adults with COVID-19 and

refractory shock. (a "shock-reversal" approach).[7] In addition, a recent Tang et al. (2020) demon study showed that heparin-based anticoagulant (mainly low molecular heparin weight) treatment was correlated with improved prognosis in extreme COVID-19 patients. The 28-day mortality risk for heparin users was ≤maller than for patients without coagulopathy owing to sepsis 4 (40.0 percent vs 64.2 percent, P Z 0.029) or D-dimer plus 6 times the top threshold of regular heparin users (32.8 percent vs. 52.4 percent , P Z 0.017).[8] Finally, high ACE2 behaviour is linked to reduced intensity of ARDS in RSV 70 Low ACE2 patients. Fedson et al. (2016, 2020) found that statins target host reaction for infection (endothelitis) instead of virus itself and indicated that combined therapy with ARB and statins could speed up a return to homosexuality, allowing pathogenicity.[9]

Conclusions

In brief, a horrific virus is more contagious than the 2003 SARS-CoV pandemic. No vaccination or reported unique anti-SARS- CoV-2 medication protocol is currently available to treat seriously ill patients. The majority of possible COVID-19 medicines are being investigated for protection and effectiveness against SARS-CoV-2. The most active agent is Remdesivir. Favopiravir and hydroxychloroquine + azithromycin combination therapy also seems to be appropriate approaches to the care of COVID-19 patients. The ACE inhibitor and ARB must be scripted carefully for patients suffering from SARS- CoV-2 infection. Acetaminophen may be a better fever treatment agent in COVID-19 patients than NSAIDs. Low-dose steroids (hydrocortisone) can eventually be recommended for refractory shock therapy in COVID-19 patients.

References

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J Am Med Assoc*. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648
2. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. *Crit Care*. 2020;24(1):6-7. doi:10.1186/s13054-020-2818-6
3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with

SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5

4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733. doi:10.1056/nejmoa2001017
5. Kumar D. Corona Virus: A Review of COVID-19. *Eurasian J Med Oncol*. 2020;4(2):8-25. doi:10.14744/ejmo.2020.51418
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
7. Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium. *J Virol*. 2013;87(11):6150-6160. doi:10.1128/jvi.03372-12
8. Jean S-S, Chang Y-C, Lin W-C, Lee W-S, Hsueh P-R, Hsu C-W. Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. *J Clin Med*. 2020;9(1):275. doi:10.3390/jcm9010275
9. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*. 2020;382(10):929-936. doi:10.1056/nejmoa2001191